12:00 AM
 | 
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zybrestat fosbretabulin regulatory update

OxiGene said the European Commission granted Orphan Drug designation for Zybrestat fosbretabulin to treat ovarian cancer. The A4 prodrug phosphatase-activated tumor vascular targeting agent is...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >